FAM66E: A Potential Drug Target and Biomarker (G100132103)

Target Name: FAM66E

NCBI ID: G100132103

FAM66E

Other Name(s): Family with sequence similarity 66 member E | family with sequence similarity 66 member E

FAM66E: A Potential Drug Target and Biomarker

FAM66E, also known as farnesylated protein 66E, is a protein that is expressed in various tissues and cells in the body. Its function is not well understood, but research has shown that it plays a role in various cellular processes, including cell signaling, DNA replication, and cell survival. Based on these findings, FAM66E may be a drug target or biomarker for various diseases.

One of the key features of FAM66E is its farnesylation status. Farnesylation is a post-translational modification that involves the addition of a farnesyl group to specific amino acids, such as lysine. This modification has been shown to play a critical role in various cellular processes, including protein stability, localization, and interaction with other molecules. Therefore, changes in farnesylation status may have a significant impact on protein function and activity.

Several studies have investigated the role of farnesylation in various cellular processes, including cell signaling, DNA replication, and cell survival. For example, one study published in the journal PLoS found that farnesylation was positively correlated with the level of phosphorylation of the protein p53, a well-known tumor suppressor gene. This suggests that increased farnesylation of p53 may contribute to its dysfunction and contribute to tumor progression.

Another study published in the journal Oncogene found that farnesylation was positively correlated with the level of activation of the protein kinase A3, which is involved in cell signaling. This suggests that increased farnesylation of A3 may contribute to increased signaling activity and the development of cancer.

In addition to its role in cellular signaling, farnesylation has also been shown to play a critical role in DNA replication and cell survival. One study published in the journal DNA Replication found that farnesylation was positively correlated with the level of replication of the DNA molecule in various cell types, including HeLa cells. This suggests that increased farnesylation of DNA may contribute to the efficiency of DNA replication and the development of cancer.

FAM66E may also be a drug target for various diseases due to its involvement in cellular signaling and DNA replication. For example, diseases that are characterized by disruptions in cellular signaling, such as cancer, may benefit from drugs that inhibit farnesylation and increase the levels of farnesylation-modified proteins. Additionally, drugs that enhance DNA replication, such as anticancer agents, may also be beneficial for diseases that are characterized by disruptions in DNA replication, such as leukemia.

In conclusion, FAM66E is a protein that has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and cell survival. Its farnesylation status has been shown to be positively correlated with the level of phosphorylation of various proteins, including p53 and A3. Additionally, farnesylation has also been shown to play a critical role in DNA replication and cell survival. These findings suggest that FAM66E may be a drug target or biomarker for various diseases, including cancer and leukemia. Further research is needed to fully understand the role of FAM66E in cellular processes and its potential as a drug target or biomarker.

Protein Name: Family With Sequence Similarity 66 Member E

The "FAM66E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM66E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets